Seoul, South Korea

Jun Young Son

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Paean Biotechnology Inc.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 15.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Jun Young Son in Myositis Treatment

Introduction

Jun Young Son is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of myositis. His innovative approach has led to the development of a unique pharmaceutical composition that utilizes isolated mitochondria as an active ingredient.

Latest Patents

Jun Young Son holds a patent for a pharmaceutical composition aimed at preventing or treating myositis. The patent is titled "PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MYOSITIS, COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT." This invention highlights his commitment to advancing medical treatments and improving patient outcomes.

Career Highlights

Currently, Jun Young Son is associated with Paean Biotechnology Inc., where he continues to work on innovative solutions in the pharmaceutical industry. His expertise and dedication have positioned him as a key figure in the development of new therapeutic strategies.

Collaborations

Throughout his career, Jun Young Son has collaborated with notable colleagues, including Hahnsun Jung and Sang-Min Lim. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and enhances the innovation process.

Conclusion

Jun Young Son's contributions to the field of pharmaceuticals, particularly in the treatment of myositis, demonstrate his innovative spirit and dedication to improving healthcare. His work continues to inspire advancements in medical science and offers hope for patients affected by this condition.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…